Re: Late Effects From Radiation Therapy: The Hits Just Keep on Coming

Aleman et al remark on Longo's recent editorial regarding their article on the increased risk of stroke and transient ischemic attack following Hodgkin lymphoma. Longo criticized the use of radiotherapy in the treatment of Hodgkin lymphoma and stated that chemotherapy is as effective as combine...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 2010-04, Vol.102 (8), p.576-577
Main Authors: Aleman, Berthe M. P., de Bruin, Marie L., Dorresteijn, Lucille D. A., Krol, Augustinus D. G., van ‘t Veer, Mars B., Boogerd, Willem, van Leeuwen, Flora E.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Dose-Response Relationship, Radiation
Editorials
Heart - radiation effects
Hodgkin Disease - drug therapy
Hodgkin Disease - radiotherapy
Humans
Ischemia
Ischemic Attack, Transient - epidemiology
Ischemic Attack, Transient - etiology
Lymphoma
Meta-analysis
Radiation Injuries - complications
Radiation Injuries - epidemiology
Radiation Injuries - etiology
Radiation Injuries - prevention & control
Radiotherapy - adverse effects
Radiotherapy Dosage
Risk Assessment
Risk Factors
Stroke
Stroke - epidemiology
Stroke - etiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aleman et al remark on Longo's recent editorial regarding their article on the increased risk of stroke and transient ischemic attack following Hodgkin lymphoma. Longo criticized the use of radiotherapy in the treatment of Hodgkin lymphoma and stated that chemotherapy is as effective as combined modality treatment and proven to be safe. They argue that Longo overestimated the efficacy of chemotherapy alone in the treatment of Hodgkin lymphoma while at the same time underestimating the toxicity of this treatment. On the other hand, Longo expresses that as a practical matter, even if one grants the unproven assertion that combined modality therapy is more effective than chemotherapy alone in early-stage Hodgkin's disease, it's clear from the meta analysis that the margin is 10% or less.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/djq069